RecruitingPhase 2Drug trialGuselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)A single-arm open-label study assessing short-term (week 6, 16) and long-term (week 32) efficacy of guselkumab in adult participants with pyoderma gangrenosum (PG)